Inspection classificationInspection ended June 24, 2026
FDA inspection of Novartis Pharmaceuticals Corporation: NAI
No action indicated
FDA classified an inspection of Novartis Pharmaceuticals Corporation in East Hanover, NJ as NAI (no action indicated). The inspection ended on June 24, 2026. Product type: Drugs.
On the record
- Establishment
- Novartis Pharmaceuticals Corporation
- Location
- East Hanover, NJ
- Classification
- NAI · No action indicated
- Inspection ended
- 2026-06-24
- Product type
- Drugs
- Fiscal year
- FY2026
- FDA establishment identifier (FEI)
- 2210396
- Source
- FDA Data Dashboard ↗
The full record
An account shows the project areas inspected and whether citations were posted.
What an inspection classification is
After an inspection FDA classifies the outcome. NAI (no action indicated): no objectionable conditions were found, or none that justify further action. VAI (voluntary action indicated): objectionable conditions were found, but the agency is not prepared to take or recommend regulatory action. OAI (official action indicated): regulatory or administrative action is recommended.
More
Watch Novartis Pharmaceuticals Corporation
A free account shows the last 7 days of every record. Pro adds a watchlist: one email when FDA acts on a company you name.
From FDA Data Dashboard; FDA posts a classification after its review, which can be months after the inspection ended. The record may have changed since it was read.
Approve Suite is not affiliated with FDA, or with Novartis Pharmaceuticals Corporation.
See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.